Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies. (2022). SKIN The Journal of Cutaneous Medicine, 6(2), s11. https://doi.org/10.25251/skin.6.supp.11